| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10907974 | Experimental Hematology | 2005 | 11 Pages |
Abstract
This study establishes (1) a threshold level for MRD above which prognosis is worse, (2) that stem cell products from 69% of patients have higher than this “safe” MRD level, and (3) that ET-18-OCH3 and hyperthermia may be used to purge products in part of these patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Nicole Feller, Martine C. Jansen-van der Weide, Marjolein A. van der Pol, Guus A.H. Westra, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis,